Singapore biotech firm Tychan on final stage trials for Covid-19 antibody
In October, HSA gave Tychan the green light to start final-stage trials. - TYCHAN SINGAPORE (The Straits Times/ANN): The final phase of the clinical trial for a Covid-19 antibody developed by Singapore biotechnology company Tychan began on Friday (Dec 11). The antibody can potentially help patients with the coronavirus to recover faster, while slowing the progression of the infection. Some 1,305 patients who have tested positive for Covid-19 will take part voluntarily in the clinical trials. If the clinical trials are successful, the antibody will be submitted for review by the Health Science...
Source: thestar.com.my
